Overview A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke Status: Not yet recruiting Trial end date: 2025-07-12 Target enrollment: Participant gender: Summary This phase II clinical study is designed to evaluate the safety and efficacy of LT3001 in the treatment of acute ischemic stroke Phase: Phase 2 Details Lead Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd